Table 1.
Summary of Ongoing and recently Completed Clinical Trials for AS This table provides an overview of interventional studies currently evaluating or recently completing evaluation of investigational therapies in AS, including mechanism of action, target population, and study status
| Study name | Drug | Mechanism | Population | Status | Sponsor |
|---|---|---|---|---|---|
| EPPIK | Sparsentan | Dual ETA/AT1 receptor blocker | Pediatrics & Adolescents |
Recruiting (Phase 2) |
Travere Therapeutics |
| ALPESTRIA-1 | Vonafexor | FXR agonist | Adolescents & Adults |
Active, not recruiting (Phase 2) |
ENYO Pharma |
| ELX-02 | ELX-02 | Read-through compound (COL4 mutations) | Pediatrics & Adults |
Ongoing (Phase 2) |
Eloxx Pharmaceuticals |
| FIONA | Finerenone | Non-steroidal MRA | Pediatrics & Adults |
Recruiting (Phase 3) |
Bayer |
| R3R01-201 | R3R01 | Mediates cholesterol efflux by ABCA1 induction | Adolescents & Adults |
Completed (Phase 2) |
River 3 Renal Corporation |
| VAR200-0301 | 2HPβCD | Mediates cholesterol efflux | Adults |
Ongoing (Phase 2) |
ZyVersa |
| hUC-MSC | hUC-MSC |
Stem cell therapy (anti-inflammation) |
Pediatrics |
Planned (Phase 2) |
Guangzhou Women& Children’s Medical Center |
| Setanaxib | Setanaxib |
NOX1/4 inhibitor (anti-fibrotic) |
Adolescents & Adults |
Completed (Phase 2) |
Calliditas Therapeutics |
| AFFINITY | Atrasentn | Selective ETA receptor antagonist | Adults |
Active, not recruiting (Phase 2) |
Novartis Pharmaceuticals |
| CARDINAL | Bardoxolone methyl | Nrf2 activator | Adolescents & Adults |
Completed, negative (Phase 3) |
Biogen |
| EAGLE | Bardoxolone methyl | Nrf2 activator (long-term safety) | Adolescents & Adults |
Terminated (Phase 3) |
Biogen |
| HERA | Lademirsen (anti-miR-21) | microRNA inhibitor | Adolescents & Adults | Terminated for futility | Sanofi |
| DOUBLE PRO-TECT Alport | Dapagliflozin | SGLT2 inhibitor | Adolescents & Young Adults | Recruiting (Phase 3) | German Research Foundation DFG |